6ix — Find Your Next Investment

Discover investor relations events, company profiles, and investment opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
5m ago	WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
6m ago	Pharming Group to report first quarter 2026 financial results and provide business update on May 7
39m ago	Essity: Interim Report Quarter 1, 2026
1h ago	Teck Reports Unaudited First Quarter Results for 2026
1h ago	STMicroelectronics Reports Q1 2026 Financial Results

About

Wuxi Biologics (HK:2269) — investor relations, events, news, and company updates on 6ix.

Latest News

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

Financials

Revenue

HK$21.79 B

Market Cap

HK$144.59 B

P/E Ratio

26.50

EPS

0.99

Community Chat

Ask AI